Hodgkin's lymphoma medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 9: Line 9:


===Chemotherapy===
===Chemotherapy===
* Drug Regimen: ''[[ABVD]]''[[Adriamycin]] {{and}} [[Bleomycin]] {{and}} [[Vinblastine]] {{and}} [[Dacarbazine]]
 
* Drug Regimen: [[Stanford V]] [[Adriamycin]] {{and}}  [[Bleomycin]] {{and}} [[Vinblastine]] {{and}} [[Mechlorethamine]] {{and}} [[Etoposide]] {{and}} [[Prednisone]] {{and}} [[RT]].
* Drug Regimen: (MOPP) [[Mustargen]] {{and}} [[Oncovin]] {{and}} [[Prednisone]] {{and}} [[Procarbazine]]
* Drug Regimen: [[BEACOPP]] [[Bleomycin]] {{and}} [[Etoposide]] {{and}} [[Adriamycin]] {{and}} [[Cyclophosphamide]] {{and}} [[Oncovin]] {{and}} [[Procarbazine]] {{and}} [[Prednisone]]
 
* Drug Regimen: (''[[ABVD]]'') [[Adriamycin]] {{and}} [[Bleomycin]] {{and}} [[Vinblastine]] {{and}} [[Dacarbazine]]
* Drug Regimen: ([[Stanford V]]) [[Adriamycin]] {{and}}  [[Bleomycin]] {{and}} [[Vinblastine]] {{and}} [[Mechlorethamine]] {{and}} [[Etoposide]] {{and}} [[Prednisone]] {{and}} [[Radiation therapy]].
* Drug Regimen: ([[BEACOPP]]) [[Bleomycin]] {{and}} [[Etoposide]] {{and}} [[Adriamycin]] {{and}} [[Cyclophosphamide]] {{and}} [[Oncovin]] {{and}} [[Procarbazine]] {{and}} [[Prednisone]]


With appropriate treatment, over 93% of Hodgkin's lymphoma cases are curable.
With appropriate treatment, over 93% of Hodgkin's lymphoma cases are curable.

Revision as of 20:27, 8 September 2015

Hodgkin's lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hodgkin's lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray Findings

CT

MRI

Ultrasound

Biopsy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hodgkin's lymphoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hodgkin's lymphoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hodgkin's lymphoma medical therapy

CDC on Hodgkin's lymphoma medical therapy

Hodgkin's lymphoma medical therapy in the news

Blogs on Hodgkin's lymphoma medical therapy

Directions to Hospitals Treating Hodgkin's lymphoma

Risk calculators and risk factors for Hodgkin's lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Overview

Patients with early stage disease (IA or IIA) are effectively treated with radiation therapy or chemotherapy. The choice of treatment depends on the age, sex, bulk and the histological subtype of the disease. Patients with later disease (III, IVA, or IVB) are treated with combination chemotherapy alone. Patients of any stage with a large mass in the chest are usually treated with combined chemotherapy and radiation therapy.

Medical Therapy

Chemotherapy

With appropriate treatment, over 93% of Hodgkin's lymphoma cases are curable.

The high cure rates and long survival of many patients with Hodgkin's lymphoma has led to a high concern with late adverse effects of treatment, including cardiovascular disease and second malignancies such as acute leukemias, lymphomas, and solid tumors within the radiation therapy field. Most patients with early stage disease are now treated with abbreviated chemotherapy and involved-field radiation therapy rather than with radiation therapy alone. Clinical research strategies are exploring reduction of the duration of chemotherapy and dose and volume of radiation therapy in an attempt to reduce late morbidity and mortality of treatment while maintaining high cure rates. Hospitals are also treating those who respond quickly to chemo-therapy with no radiation.

References


Template:WikiDoc Sources